How to Buy an Independent Pharmacy in 2026

Independent pharmacy acquisitions are one of the more misunderstood corners of the healthcare M&A market. On paper, the economics look ugly — DIR fees, PBM clawbacks, Walgreens and CVS closing thousands of stores, script volume declining at the chains. Every week a new headline suggests the independent pharmacy is dead. And yet I keep seeing strong buyers — pharmacists, physician groups, and small PE-backed platforms — aggressively acquiring independents at 2.5-4.5x EBITDA and generating 20%+ cash-on-cash returns.

The disconnect is that the chain store model and the independent model are not the same business. If you understand what actually drives profitability at an independent, you can buy a pharmacy for $600K that throws off $200K a year and builds real wealth. Here is how to do it properly.

What You Are Actually Buying

An independent pharmacy is three businesses stacked on top of each other. The first is the traditional retail dispensing business — commercial and Medicare Part D scripts reimbursed through PBM contracts. Margins here are razor thin, usually 18-22% gross and 3-5% net after DIR fees get clawed back six months later. This is the part everyone reads about in the trade press, and it is genuinely under pressure.

The second business is the specialty and compliance layer — adherence packaging, med sync, long-term care (LTC) contracts with assisted living facilities, compounding, durable medical equipment (DME), and point-of-care testing. Margins here run 35-55% and the revenue is sticky because it is tied to facility contracts or patient routines rather than whoever has the lowest copay this month.

The third business, if the store qualifies, is 340B contract pharmacy revenue through partnerships with federally qualified health centers (FQHCs), Ryan White clinics, disproportionate share hospitals (DSH), or critical access hospitals. A single well-structured 340B contract can add $150K-$600K of annual EBITDA to a store that looked mediocre on its unadjusted financials. If you are not pricing 340B optionality into your offer, you are leaving the most valuable piece of the deal on the table.

How Independent Pharmacies Actually Get Valued

Most independent pharmacy deals trade on a combination of SDE or EBITDA plus inventory at cost. The multiple range I see most often in 2026 is 2.0-3.5x SDE for single-store retail operations, 3.5-5.0x EBITDA for stores with meaningful LTC or specialty exposure, and 5.0-7.5x EBITDA for multi-store platforms or stores with locked-in 340B revenue.

Inventory is valued separately and added on top — typically $150K-$400K at cost for a single store, and this is real money the seller expects to walk away with. Do not forget to negotiate an inventory cap; I have seen sellers intentionally stockpile slow-moving product in the 60 days before closing to pad their payout.

The adjustments that matter most during diligence are DIR fee normalization (pull the last three years of actual clawbacks from the PBM reconciliation reports, not the seller's P&L), owner comp add-backs if the pharmacist-owner is also the PIC, and a haircut on any revenue tied to single-physician referral relationships that will not transfer.

PSAO Membership and Why It Is Non-Negotiable

No independent pharmacy in the United States negotiates directly with PBMs anymore. You join a Pharmacy Services Administration Organization (PSAO) that negotiates reimbursement rates on your behalf. The four PSAOs that control the vast majority of independent pharmacy contracts are AmerisourceBergen's Elevate Provider Network, Cardinal Health's Leader PSAO, McKesson's Health Mart Atlas, and the independently owned EPIC Pharmacies. Your PSAO is typically bundled with your primary wholesaler agreement.

When you acquire a pharmacy, you need to confirm three things about the PSAO relationship during diligence. First, whether the contract transfers automatically on a change of ownership or whether you need to re-enroll (most require re-enrollment and a fresh credentialing packet). Second, whether the seller is in good standing — PSAOs can and do terminate stores for DIR performance issues, and an at-risk store is much harder to finance. Third, what the effective reimbursement differential is between PSAOs in your market, because switching can move gross margin 1-2 percentage points on $4M of revenue, which is real EBITDA.

On the wholesaler side, expect to sign a 3-5 year primary vendor agreement with ABC, Cardinal, or McKesson as a condition of taking over the store. Your generic compliance rate (usually 95%+) and your minimum monthly purchase volume are both baked into your cost of goods. Negotiate these before closing, not after.

The 340B Opportunity Most Buyers Miss

The 340B Drug Pricing Program allows covered entities (FQHCs, Ryan White grantees, DSH hospitals, critical access hospitals, and a handful of others) to purchase outpatient drugs at deeply discounted prices and then dispense them through contract pharmacies. The covered entity captures most of the spread, but the contract pharmacy gets a dispensing fee plus a share of the savings — typically $15-$40 per script, versus $2-$6 per commercial script.

If you are buying a pharmacy near an FQHC, a Ryan White clinic, or a rural hospital and the seller has not set up a 340B contract, that is your value creation thesis in one bullet point. A store doing 250 scripts a day might convert 30-60 of them to 340B within 12-18 months of closing and add $150K-$400K to annual EBITDA with essentially zero incremental fixed cost.

Be aware that manufacturer 340B restrictions have been tightening since 2020 — Lilly, Sanofi, Novo Nordisk, and others now limit contract pharmacy dispensing for certain drugs. This is real and needs to be modeled, but it has not killed the economics. It has just made the analysis more complicated.

Financing the Deal

Pharmacy acquisitions are one of the SBA 7(a) program's favorite asset classes because the business has real inventory, recurring script revenue, and a licensed professional operator. Expect to put 10-15% down on a deal up to $5M, with the SBA guaranteeing 75% of the loan and a 10-year amortization. Live Oak Bank, Byline Bank, and Huntington are the most active SBA lenders in pharmacy right now and all have dedicated healthcare underwriting teams.

For deals above $5M or multi-store rollups, you move into conventional healthcare lending — First Financial Bank, Fifth Third's healthcare group, and several specialty finance shops will do senior debt at 3.5-4.5x EBITDA with cash sweeps and covenant packages similar to any lower-middle-market healthcare deal.

Seller financing is common and useful. A 10-15% seller note at 6-8% for 5-7 years keeps the seller motivated during the transition, satisfies SBA equity requirements, and gives you a lever if something was misrepresented during diligence. Do not skip this just because the seller wants all cash.

Due Diligence Items That Actually Matter

Pharmacy diligence is different from most small business diligence because the financial statements understate how much of the business is regulated and contract-dependent. Focus your time here:

• DEA registration and state board inspection history. Pull the last three inspection reports. CII (Schedule II) discrepancies, missing 222 forms, or any prior DEA administrative action will delay your license transfer by months.
• PBM credentialing and audit exposure. Ask for the last 36 months of PBM audits. Caremark and Express Scripts audits can result in six-figure recoupments that are the seller's liability — until they aren't, because the seller is gone.
• DIR fee reconciliations. Pull the actual quarterly DIR statements, not the seller's summary. Reconcile them to the P&L. This is the single biggest source of EBITDA overstatement I see in pharmacy deals.
• LTC contracts. Read every assisted living and group home contract. Term, termination-for-convenience clauses, and any preferred provider language all determine whether the revenue survives closing.
• Compounding USP 795/797/800 compliance. If the store compounds, the facility needs to meet current USP standards. Remediation can run $40K-$150K and you want to know before you close.
• Accounts receivable aging. Third-party AR over 90 days is usually uncollectible. Price it at zero and make the seller eat it.

The Transition Playbook

Pharmacy customers are loyal, but the loyalty is to the pharmacist behind the counter, not the store name. If the selling pharmacist walks out the door on closing day, you will lose 15-25% of script volume in the first 90 days. Every deal I have seen work cleanly has included a minimum 90-day transition period where the seller stays on payroll as a staff pharmacist, introduces you to the regulars, and transfers the informal knowledge that never makes it into an operations manual.

Budget for a new POS and pharmacy management system if the store is running old software — QS/1, PioneerRx, Liberty, and BestRx are the current options and a conversion runs $15K-$40K plus two weeks of staff training. Do not skip this; an outdated system will cost you more in lost efficiency than the conversion itself.

If you are planning to use the store as a platform for a multi-store rollup, start documenting SOPs on day one. The second store is three times easier to buy and integrate if the first one is already running on a repeatable playbook.

The Bottom Line

Independent pharmacy looks like a dying industry from the outside and is actually one of the better risk-adjusted acquisition opportunities in healthcare if you know what you are looking for. The winners are buyers who can see past the chain-store narrative, price 340B and LTC optionality correctly, and execute a disciplined transition. Run the valuation calculator on the target before you make an offer — and price in every adjustment you can defend, because the seller certainly will.